Objective: Weight gain is a risk factor for metabolic syndrome (MS). However, it is not known whether weight fluctuations (WF) have a deleterious effect upon MS risk. In the present study, we investigated this association in subjects participating in the SU.VI.MAX cohort. Methods: MS status was assessed at baseline (1994/1995) and at the end of follow-up (2001/2002) using the National Cholesterol Education Program-Adult Treatment Panel III criteria. WF were estimated with four weight measures during followup. Odds ratio (OR, 95% confidence interval (CI)) for incident MS cases was evaluated according to four WF groups (no WF and tertiles of WF) in 3553 middle-aged subjects. Results: The OR (95% CI) for MS was 2.06 (1.20-3.52) for the third WF tertile compared to the first tertile. This association was independent of confounding variables, especially relative weight change during follow-up. Subjects without WF had a 2.72-fold increase (1.64-4.53) for MS risk compared to the first tertile of WF. For MS components taken separately, similar associations were found for raised blood pressure, low high-density lipoprotein-cholesterol and increased waist circumference. Conclusion: Our results showed that WF was an independent risk factor for MS after 7 years of follow-up. Moreover, subjects without WF were also at risk for MS, due to the highest weight gain during follow-up. These results support the benefits of weight stability and emphasize the importance of weight gain prevention starting from early adulthood.
Introduction
Obesity is known to be associated with increased cardiovascular disease (CVD) morbidity and mortality. 1, 2 Attempts to control body weight are not only prevalent among the obese but in normal-weight subjects as well. 3 However, weight reduction is difficult to maintain and weight regain is frequent, leading to repeated cycles of weight loss and recovery, popularly referred to as 'yo-yo dieting'. 4, 5 Although there is a general agreement that modest weight loss has beneficial health effects in obese patients, 6 there are some hypotheses that suggest that weight cycling could be damaging particularly for CVD risk. 7, 8 However, studies investigating the effect of weight variability on CVD risk have shown controversial results. Some studies indicated that the overall weight trend had a greater deleterious effect on CVD risk than weight fluctuation (WF) (that is the WF effect was not significant after adjustment for weight change), [9] [10] [11] whereas others concluded that WF had an independent effect. [12] [13] [14] [15] [16] [17] These contradictions could be attributed to differences in methods used for the assessment of WF. Since there is no existing consensus for WF definition, it is difficult to make comparisons between studies. One of the mechanisms for the increased CVD risk with WF may be through the effect of WF on metabolic syndrome (MS), a potential CVD risk factor. The MS is characterized by an insulin-resistant status in addition to a cluster of abnormalities such as high blood pressure (BP), elevated triglycerides (TG), low high-density lipoprotein-cholesterol (HDL-c), high fasting glucose and increased waist circumference (WC). 2 It is documented that MS is associated with an increased risk of ischemic heart disease [18] [19] [20] [21] and increased level of intermediate CVD markers. 22 To our knowledge, only one cross-sectional study has investigated the association between WF and the risk of MS and found an increased MS risk with WF. 23 The aims of the present study were to (1) investigate the relationship between WF over 7 years and the risk for MS and (2) to identify whether WF and weight gain convey different risks for MS in middle-aged French men and women included in the SU.VI.MAX ('SUpplémentation en VItamines et Minéraux Anti-oXydants') study.
Methods

Subjects
Subjects were participants of the SU.VI.MAX study which was a randomized double-blind, placebo-controlled, primary prevention trial initially designed to test the efficacy of a daily antioxidant supplementation at nutritional doses in reducing the incidence of ischemic heart disease and cancer. 24, 25 Among the 13,017 subjects included, two-thirds were women aged 35-60 years and one-third were men aged 45-60 years. The SU.VI.MAX study was approved by the Ethical Committee for Studies with Human Subjects at the Paris-Cochin Hospital (CCPPRB number 706) and the 'Commission Nationale de l'Informatique et des Libertés' (CNIL number 334641), which ensures that medical information is kept confidential and anonymous. Participants were invited yearly to attend either a biological examination (from 1994 onward) or a clinical examination (from 1995 onward). For the present analyses, subjects who attended the last medical visit (from January 2001 to June 2002) and for whom data for defining the MS were available at this time point were included (n ¼ 5858). The sample was also restricted to subjects with complete anthropometric data during the 7.5 years of follow-up and covariables (n ¼ 4230). We excluded subjects with a past history of cancer or CVD and those who had such events during follow-up, in order to exclude potential unintentional weight loss (n ¼ 3965). Finally, we excluded subjects with MS (or each MS component taken separately) at baseline in order to determine the association between WF and incident cases of MS (or each MS components). In total, 3553 subjects were included in the present report for MS analyses.
Clinical and biological variables
We used four weight values for each subject: self-reported weight at enrollment (1994/1995) and measured weight during follow-up (1995/1996, 1998 and 2001) . Weight was measured with an electronic scale (Seca, Hamburg, Germany) with subjects in indoor clothing and no shoes. Height was measured under the same conditions to the nearest 0.5 cm with a wall-mounted stadiometer. Body mass index (BMI) was calculated as weight divided by height squared (kg m
À2
).
We used data collected at the first biological (1994/1995) and clinical (1995/1996) examinations for characterizing MS status at baseline and data collected at the last medical visit (both biological and clinical, from January 2001 to June 2002) for characterizing MS status at the end of follow-up. WC was measured as the circumference midway between the lower ribs and iliac crest in standing position using an inelastic tape with subjects in indoor clothing. Systolic and diastolic BP were measured one time on each arm using a standard mercury sphygmomanometer in subjects who had been lying down for 10 min. The average of the two measurements was used for analyses. If systolic BP was above 160 mm Hg or diastolic BP was above 90 mm Hg, BP was measured after another 5 min rest. The lowest measurement was kept as the reference BP. Fasting blood glucose, HDL-c and TG were measured using an enzymatic method (Advia 1650, Bayer Diagnostic, Puteaux, France). Level of education (primary, secondary, university or equivalent) and smoking status were obtained from a questionnaire at baseline. Physical activity was assessed from the same questionnaire using the following questions: 'Do you regularly practice physical activity (transportation, work, leisure): yes/no?' and 'if yes, is this physical activity greater than or less than the equivalent of 1 h of brisk walking per day?'. Physical activity was coded in three categories: irregular physical activity, regular and o1 h day À1 , regular and X1 h day
À1
. This variable has been shown to be strongly associated with obesity in both men and women from the SU.VI.MAX. cohort. 26 Weight fluctuation definition Two methods for coding WF have been used in the literature. 27 The first one is qualitative and classifies subjects according to WF previously determined cut-off points (for example, losing and regaining X4.5 kg, 10 times or more since completion of puberty 28 ). Since there are no standardized cut-off points yet available, 27 this decision is left to the investigator and may induce a classification bias. Moreover, these variables are most often determined by retrospective measures whose limitations are already known. 29 A more objective estimation can be achieved by using a continuous variable determined by measured weights. The method most commonly used is the root mean square error (RMSE). Using a linear regression model of weight on age for each subject, weight variability is divided into the slope (that is the regression coefficient which represents the trend index) and the RMSE (that is the standard error around the linear slope which represents the WF index). 30 The RMSE method assumes that the overall weight gain trend is linear, which is not often the case. Figure 1 gives three typical examples of weight variability. In the first example, the subject gains weight between each examination, but not in a linear way.
In the second one, the subject has one weight cycle (a weight loss followed by a weight regain or a weight gain followed by a weight loss) and in the third, the subject has two prominent weight cycles. In the first example, the RMSE Weight fluctuations and metabolic syndrome A-C Vergnaud et al
gives an incorrect estimation of WF. While the subject does not have a weight cycle, the RMSE value is very high (value of 5.3) and greater than the RMSE value in the second example where the subject experiences one weight cycle (value of 3.8). Therefore, RMSE will misclassify subjects and overestimate weight cyclers. Apart from the RMSE method, other statistical approaches could be used. We propose to implement the deviation method which removes the RMSE weakness and preserves the advantages of a continuous reproducible variable. For subjects without WF (that is only those with weight gain or weight loss between each measurement), WF are fixed at 0. For subjects with WF (that is those who have at least two weight variations in opposite directions), for each weight cycle (for example a weight loss followed by a weight regain), we calculated the difference between the lowest weight of the cycle and the hypothetical weight if the subject did not experience this weight cycle (calculated from the straight line between the two highest weights of the cycle, cf Figure 1 ). This calculation is made for each weight cycle of the considered period. Two different measures can be obtained from this sequence of deviations: the maximum deviation which represents the maximum amplitude of WF and the sum of deviations which takes into account the frequency of WF. In the present study, only results for the maximum deviation are presented. Four WF groups were created: one group including subjects without WF (group 0) and three groups according to WF tertiles (T1, T2 and T3). Weight change was estimated by the difference between weight at the end of follow-up and weight at baseline. Relative weight change (weight change/weight at baseline) was used in the present analysis. ). We classified participants using antidiabetic (oral agents or insulin) or antihypertensive medications as subjects having increased fasting blood glucose or increased BP, respectively.
Definition of the MS
Statistical analyses
Descriptive results are reported as percentages or mean (m)7standard deviation. TG concentrations were log-trans- Weight fluctuations and metabolic syndrome A-C Vergnaud et al formed due to skewed distributions, therefore geometric means and 95% confidence intervals (95% CIs) are presented. Logistic regression models were used to estimate the odds ratio (OR) for having the MS (or each MS component) at the end of follow-up according to the four groups of WF (no WF and tertiles of WF). The lowest tertile of WF was considered as the reference group. All analyses were adjusted for age, sex, smoking status, education level, physical activity (model 1) and relative weight change (model 2). Statistical significance was judged at a o0.05. All statistical analyses were performed using SAS version 8.2 (SAS, Cary, NC, USA). Figure 2 . For MS risk, no interaction was found between WF and BMI at baseline or weight change (data not shown). Subjects in the third tertile of WF had a 2.06-fold increase (95% CI ¼ 1.20-3.52) for MS risk compared to the first tertile (P ¼ 0.007) after adjustment for age, sex, smoking status, education level, physical activity and relative weight change (model 2). Subjects without WF (group 0) had a 2.72-fold increase (1.64-4.53) for MS risk compared with the first tertile of WF, with no adjustment for relative weight change (model 1). Weight gain was the most important in group 0 (5.0 kg) compared to tertile of WF (0.9, 1.7 and 2.3 kg, respectively). When studying each independent MS component ( Table 2) , we found that the OR for increased BP, low HDL-c and increased WC was significantly higher for the third tertile of WF compared to the first. A similar, but nonsignificant association was observed for the two other MS components (TG X150 mg dl À1 and fasting blood glucose X110 mg dl
Results
À1
). When analyses were performed using sex-specific WF tertiles, similar results were found (data not shown). Furthermore, in our sample, the association between WF and MS risk did not depend on adiposity repartition changes. Indeed, the interaction between WF groups and WC changes between the first clinical examination and the end of follow-up on MS risk, adjusted on weight change, was not significant (data not shown). There was also no interaction between WF and the supplementation group in terms of MS risk. 
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Discussion
In the present longitudinal study, WF was a risk factor for MS and most MS components, independent of relative weight change and other confounding variables. Furthermore, our results also showed that subjects without WF had the highest weight gain during follow-up and were consequently at risk for MS compared to subjects in the first tertile of WF. No tobacco cessation occurred during the 7.5 years of follow-up in our population (data not shown) which allows us to conclude that the significant associations are not biased by this confounder. This low tobacco cessation rate might be explained by the age of the SU.VI.MAX participants and by the exclusion of all subjects with a past history or an event during follow-up of cancer or CVD. Our results provide additional evidence supporting the association between WF and the risk for MS. However, it should be noted that there is only one cross-sectional study which evaluated this association using a recent definition of the MS. 23 In 664 Japanese men aged 40-49 years and recruited in a worksite setting, a positive relationship between weight-RMSE and the risk of MS was found for subjects with BMI o25 kg m
À2
, after adjustment for current BMI, BMI at 20 years and weight slope. However these results must be interpreted with caution considering that the use of RMSE method is not valid for nonlinear weight gain. Consistent with other studies, we found no interaction between WF and weight change on the risk for MS or each MS component. 10, [31] [32] [33] There are a number of previous studies that have investigated the relationships between WF and each individual component of the MS. 10, [31] [32] [33] [34] [35] [36] [37] In our study, we found that WF had an increased risk for BP, HDL-c and WC. ORs for the fasting blood glucose and TG components followed the same trend and we assume that their nonsignificant results were related to insufficient statistical power (the number of cases was smaller than those for other components). These results are in agreement with some previous analyses. WF over time was associated with an increased risk of hypertension in obese subjects in a study investigating the effect of short-term weight change using a 2-year weight cycling period 36 (results also confirmed with a 5-year period of WF estimation 34 ). WF was also associated with an increased body fat mass, BP and TG level in nonobese young women in an intervention study testing the effect of the succession of intentional weight cycling during a 6 months follow-up period. 35 However, other studies did not support the hypothesis that WF have deleterious effect on these CVD risk factors. 10, [31] [32] [33] 37 These contradictions could be attributed to the different methods used for estimating WF. There is no single definition of weight cycling which makes comparisons between studies difficult. We have found in the present study that the most prevalent MS abnormality was increased BP. This is in agreement 39 On the contrary, the most prevalent MS abnormality in the NHANES III survey was increased WC. 40 These variations in the prevalence of MS components between populations suggest that MS as a whole may correspond to different clinical and metabolic situations according to the studied population. Some limitations of our study should be mentioned. Weight data were measured in 1996, 1998 and 2001, but were declared data at baseline (1994). This may have induced a classification bias. 29 However, a previous publication showed close concordance between self-reported and measured weights. 41 Second, measures of weight were available every 2 years on average. We could not detect variations occurring over a short period of time. However, using the sum of deviations for WF estimation, we found no significant relations between WF and the risk of MS or MS components (data not shown). This result indicates that the amplitude, rather than the frequency of WF has a greater impact on MS risk, suggesting that small weight interventions have little impact on MS risk compared to large WF that contribute to the 'yo-yo dieting' phenomena. Finally, we were unaware about the intentionality of weight change. Since preexisting illness may lead to unintentional weight loss, we excluded all subjects with conditions known to result in an involuntary weight change to avoid such potential confounding biases. 42, 43 However, there are several strengths in our study. First, it has a longitudinal design with a 7-year follow-up, which allows to estimate incident MS risk. Second, whereas some previous papers used the RMSE method 10, 23, 33 for WF estimation, we used a continuous reproducible WF estimation. This original statistical method developed to analyze longitudinal weight data could be used for other settings. In our analyses, a third of subjects without weight cycling would have been misclassified by the use of the RMSE method (data not shown). We have observed that both severe weight cyclers and subjects without WF were at risk for developing MS. Subjects in the first tertile of WF who have the lowest risk for MS had a higher level of education, lower BMI and had less weight variation (data not shown). These subjects were likely those who carefully monitored their weight and maintained a stable weight.
In conclusion, we have shown that WF was an independent risk factor for MS after 7 years of follow-up. Moreover, subjects without WF were also at risk for MS because they had the highest weight gain during follow-up. These results support the benefits of weight maintenance and emphasize the importance of weight gain prevention starting from early adulthood. WF should be monitored in children and adult cohorts in order to assess in other settings the potential predictive value of this anthropometric indicator on MS risk. Furthermore, the predictive value of WF, compared to weight gain, should be evaluated on CV and cancer risks.
